دورية أكاديمية
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
| العنوان: | Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. |
|---|---|
| المؤلفون: | van den Bent, Martin J, Tesileanu, C Mircea S, Wick, Wolfgang, Sanson, Marc, Brandes, Alba Ariela, Clement, Paul M, Erridge, Sarah, Vogelbaum, Michael A, Nowak, Anna K, Baurain, Jean-François, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà , Roberta, Weller, Michael, McBain, Catherine, Reijneveld, Jaap, Enting, Roelien H, Caparrotti, Francesca, Lesimple, Thierry, Clenton, Susan, Gijtenbeek, Anja, Lim, Elizabeth, Herrlinger, Ulrich, Hau, Peter, Dhermain, Frederic, de Heer, Iris, Aldape, Kenneth, Jenkins, Robert B, Dubbink, Hendrikus Jan, Kros, Johan M, Wesseling, Pieter, Nuyens, Sarah, Golfinopoulos, Vassilis, Gorlia, Thierry, French, Pim, Baumert, Brigitta G |
| المساهمون: | UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer |
| المصدر: | The Lancet. Oncology, Vol. 22, no.6, p. 813-823 (2021) |
| بيانات النشر: | Lancet Pub. Group |
| سنة النشر: | 2021 |
| المجموعة: | DIAL@UCL (Université catholique de Louvain) |
| مصطلحات موضوعية: | Adolescent, Adult, Aged, Australia, Chemotherapy, Adjuvant, Chromosomes, Human, Pair 1, Pair 19, Combined Modality Therapy, Dacarbazine, Europe, Female, Glioma, Humans, Isocitrate Dehydrogenase, Loss of Heterozygosity, Male, Middle Aged, North America, Radiotherapy, Conformal, Temozolomide, Young Adult |
| الوصف: | BACKGROUND: The CATNON trial investigated the addition of concurrent, adjuvant, and both current and adjuvant temozolomide to radiotherapy in adults with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas. The benefit of concurrent temozolomide chemotherapy and relevance of mutations in the IDH1 and IDH2 genes remain unclear. METHODS: This randomised, open-label, phase 3 study done in 137 institutions across Australia, Europe, and North America included patients aged 18 years or older with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas and a WHO performance status of 0-2. Patients were randomly assigned (1:1:1:1) centrally using a minimisation technique to radiotherapy alone (59·4 Gy in 33 fractions; three-dimensional conformal radiotherapy or intensity-modulated radiotherapy), radiotherapy with concurrent oral temozolomide (75 mg/m2 per day), radiotherapy with adjuvant oral temozolomide (12 4-week cycles of 150-200 mg/m2 temozolomide given on days 1-5), or radiotherapy with both concurrent and adjuvant temozolomide. Patients were stratified by institution, WHO performance status score, age, 1p loss of heterozygosity, the presence of oligodendroglial elements on microscopy, and MGMT promoter methylation status. The primary endpoint was overall survival adjusted by stratification factors at randomisation in the intention-to-treat population. A second interim analysis requested by the independent data monitoring committee was planned when two-thirds of total required events were observed to test superiority or futility of concurrent temozolomide. This study is registered with ClinicalTrials.gov, NCT00626990. FINDINGS: Between Dec 4, 2007, and Sept 11, 2015, 751 patients were randomly assigned (189 to radiotherapy alone, 188 to radiotherapy with concurrent temozolomide, 186 to radiotherapy and adjuvant temozolomide, and 188 to radiotherapy with concurrent and adjuvant temozolomide). Median follow-up was 55·7 months (IQR 41·0-77·3). The second interim analysis declared futility of concurrent ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1470-2045 1474-5488 |
| العلاقة: | boreal:264022; http://hdl.handle.net/2078.1/264022Test; info:pmid/34000245; urn:ISSN:1470-2045; urn:EISSN:1474-5488 |
| DOI: | 10.1016/S1470-2045(21)00090-5 |
| الإتاحة: | https://doi.org/10.1016/S1470-2045Test(21)00090-5 http://hdl.handle.net/2078.1/264022Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.176A855A |
| قاعدة البيانات: | BASE |
| تدمد: | 14702045 14745488 |
|---|---|
| DOI: | 10.1016/S1470-2045(21)00090-5 |